Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis

The tear film, which includes mucins that adhere to foreign particles, rapidly clears allergens and pathogens from the ocular surface, protecting the underlying tissues. However, the tear film’s ability to efficiently remove foreign particles during blinking can also pose challenges for topical drug delivery, as traditional eye drops (solutions and suspensions) are cleared from the ocular surface before the drug can penetrate into the conjunctival and corneal epithelium. In the past 15 years, there has been an increase in the development of nanoparticles with specialized coatings that have reduced affinity to mucins and are small enough in size to pass through the mucus barrier. These mucus-penetrating particles (MPPs) have been shown to efficiently penetrate the mucus barrier and reach the ocular surface tissues. Dry eye disease (DED) is a common inflammatory ocular surface disorder that often presents with periodic flares (exacerbations). However, currently approved immunomodulatory treatments for DED are intended for long-term use. Thus, there is a need for effective short-term treatments that can address intermittent flares of DED. Loteprednol etabonate, an ocular corticosteroid, was engineered to break down rapidly after administration to the ocular surface tissues and thereby reduce risks associated with other topical steroids. KPI-121 is an ophthalmic suspension that uses the MPP technology to deliver loteprednol etabonate more efficiently to the ocular tissues, achieving in animal models a 3.6-fold greater penetration of loteprednol etabonate to the cornea than traditional loteprednol etabonate ophthalmic suspensions. In clinical trials, short-term treatment with KPI-121 0.25% significantly reduced signs and symptoms of DED compared with its vehicle (placebo). Recently approved KPI-121 0.25%, with its novel drug delivery design and ease of use, has the potential to effectively treat periodic flares of DED experienced by many patients.

Download Full-text

Influence of Nitrogen-Doped Carbon Dot and Silver Nanoparticle Modified Carbon Paste Electrodes on the Potentiometric Determination of Tobramycin Sulfate: A Comparative Study

Chemosensors ◽

10.3390/chemosensors9030052 ◽

2021 ◽

Vol 9 (3) ◽

pp. 52

Author(s):

Nermine V. Fares ◽

Passant M. Medhat ◽

Christine M. El Maraghy ◽

Sherif Okeil ◽

Miriam F. Ayad

Keyword(s):

Silver Nanoparticle ◽

Carbon Nanodots ◽

Carbon Paste ◽

X Ray Diffraction ◽

Loteprednol Etabonate ◽

Carbon Paste Electrodes ◽

Transmission Electron ◽

Nernstian Slope ◽

Nitrogen Doped Carbon ◽

Modified Carbon Paste Electrodes

Two inexpensive and simple methods for synthesis of carbon nanodots were applied and compared to each other, namely a hydrothermal and microwave-assisted method. The synthesized carbon nanodots were characterized using transmission electron microscopy (TEM), ultraviolet-visible (UV-Vis), photoluminescence (PL), Fourier transform-infrared spectroscopy (FTIR), and X-ray diffraction (XRD). The synthesized microwave carbon nanodots had smaller particle size and were thus chosen for better electrochemical performance. Therefore, they were used for our modification process. The proposed electrodes performance characteristics were evaluated according to the IUPAC guidelines, showing linear response in the concentration range 10−6–10−2, 10−7–10−2, and 10−8–10−2 M of tobramycin with a Nernstian slope of 52.60, 58.34, and 57.32 mV/decade for the bare, silver nanoparticle and carbon nanodots modified carbon paste electrodes, respectively. This developed potentiometric method was used for quantification of tobramycin in its co-formulated dosage form and spiked human plasma with good recovery percentages and without interference of the co-formulated drug loteprednol etabonate and excipients.

Download Full-text

Loteprednol etabonate

Reactions Weekly ◽

10.1007/s40278-017-30946-3 ◽

2017 ◽

Vol 1654 (1) ◽

pp. 213-213

Keyword(s):

Loteprednol Etabonate

Download Full-text

A Double-masked, Placebo-controlled Evaluation of the Efficacy and Safety of Loteprednol Etabonate in the Treatment of Giant Papillary Conjunctivitis

American Journal of Ophthalmology ◽

10.1016/s0002-9394(14)70171-0 ◽

1997 ◽

Vol 123 (4) ◽

pp. 455-464 ◽

Cited By ~ 61

Author(s):

MITCHELL H. FRIEDLAENDER ◽

◽

JOHN HOWES

Keyword(s):

Efficacy And Safety ◽

Loteprednol Etabonate ◽

Controlled Evaluation ◽

Giant Papillary Conjunctivitis

Download Full-text

Antibacterials/loteprednol-etabonate/tobramycin/steroids

Reactions Weekly ◽

10.1007/s40278-022-08719-4 ◽

2022 ◽

Vol 1889 (1) ◽

pp. 40-40

Keyword(s):

Loteprednol Etabonate

Download Full-text

COMPARATIVE STUDY OF THE EFFICACY OF TOPICAL LOTEPREDNOL ETABONATE AND FLUOROMETHOLONE IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS : A RANDOMISED CONTROLLED STUDY

10.36106/ijsr/5403062 ◽

2021 ◽

pp. 8-10

Author(s):

Nandita Chaturvedi ◽

Nidhi Nidhi ◽

Malobika Bhattacharya

Keyword(s):

Side Effects ◽

Signs And Symptoms ◽

Subjective Symptom ◽

Controlled Study ◽

Vernal Keratoconjunctivitis ◽

Topical Steroids ◽

Loteprednol Etabonate ◽

Randomised Controlled Study ◽

Before And After ◽

Randomised Controlled

Introduction:Vernal keratoconjunctivitis(VKC) is a chronic, recurrent, inammatory disease of ocular surface showing seasonal exacerbation, affecting young children. Topical steroids are the mainstay in the treatment of ocular allergy, but their use should be judicious since they carry serious side effects . Loteprednol and uorometholone carry better safety prole. Present study was conducted with the aim of comparing the efcacy of these two widely used steroids.Objectives:To compare total subjective symptom score (TSSS), total objective sign score (TOSS) and side effects of medications before and after treatment at each visit.Materials & Methods:A prospective randomised controlled study was performed on 92 patients of VKC over four weeks. Patients were allotted to either of the two arms of treatment (i.e. LP 0.5% or FML 0.1%). Subjective and objective assessments of the signs and symptoms of VKC were done using standard scoring methodologies at 7, 14, 21 and 28 days post treatment. The main outcome measure was measured in terms of TSSS and TOSS before and after treatment at each visit. Secondary outcomes included side effects. Statistical analysis of the data collected was carried out.Results: Loteprednol showed greater reduction in symptoms initially but by the end of study there was no statistically signicant difference in effect between the two drugs.Conclusions: Final improvement in clinical features and safety prole, at the end of 4 weeks was similar in eyes treated with either of the two drugs. Hence, both the drugs can be safely used in the treatment of VKC.

Download Full-text